Molecules, compositions, methods and kits for applications associated with flaviviruses
First Claim
Patent Images
12. A method for controlling flavivirus entry into a cell, comprising administering to the cell an agent interfering with the expression of a flavivirus receptor protein, the receptor protein being integrin.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions.
-
Citations
51 Claims
- 12. A method for controlling flavivirus entry into a cell, comprising administering to the cell an agent interfering with the expression of a flavivirus receptor protein, the receptor protein being integrin.
- 19. A method for controlling a flavivirus entry into a cell, the cell having a plasma memebra, the method comprising administering to the cell an interfering agent functionally interfering with an ATPase in the plasma membrane of the cell.
-
21-1. A kit for controlling entry of a flavivirus into a cell, the cell having a plasma membrane, the kit comprising:
-
the flavivirus; and
an agent functionally interfering with an ATPase located in the plasma membrane of the cell, the flavivirus and the intefering agent to be used according to the method of claim 19.
-
- 23. A method for controlling a flavivirus entry into a cell, comprising administering to the cell an agent functionally interfering with a flavivirus receptor protein, the receptor protein being a neurotensin receptor.
- 28. A method for controlling entry of a flavivirus into a cell, the flavivirus exhibiting a flavivirus envelope protein, the flavivirus envelope protein comprising a domain III of the flavivirus envelope protein, the method comprising administering to the cell an agent functionally interfering with the domain III of the flavivirus envelope protein.
-
31. A method for treating a flavivirus infection in a vertebrate, the flavivirus exhibiting a flavivirus envelope protein, the flavivirus envelope protein comprising a domain III, the method comprising
administering to the vertebrate a pharmaceutically effective amount of an agent functionally inhibiting the domain III of the envelope protein of the flavivirus.
-
38. Pharmaceutical composition for the treatment of a flavivirus infection in a vertebrate, the flavivirus exhibiting an envelope protein comprising a domain III, the pharmaceutical composition comprising:
a pharmaceutically effective amount of an agent functionally inhibiting the domain III of the envelope protein and a pharmaceutically acceptable carrier, vehicle or auxiliary agent. - View Dependent Claims (39)
-
40. The pharmaceutical composition of claim 40, wherein the interfering agent is competitive ligand for the domain III.
-
41. A method for inducing immunity to a flavivirus in a vertebrate. susceptible to infection of the flavivirus, the flavivirus exhibiting an envelope protein comprising a domain ll, the method comprising:
administering to the vertebrate an immunogenic amount of a polypeptide comprising the domain III of the envelope protein of the flavivirus. - View Dependent Claims (42)
-
43. A vaccine for a flavivirus, the flavivirus exhibiting an envelope protein comprising a domain III, the vaccine comprising, as an active agent, a polypeptide comprising the domain III of the envelope protein of the flavivirus.
-
44. A method for diagnosing a flavivirus infection in a vertebrate susceptible to be infected by the flavivirus, the method comprising:
-
contacting a sample tissue from the vertebrate, with an integrin or neurotensin protein associated with an identifier;
detecting presence or absence of a flavivirus-integrin complex or flavivirus-neurotensin complex by detecting presence of the identifier. - View Dependent Claims (45)
-
-
46. A diagnostic method to analyze a cell susceptibility to flavivirus infection, the method comprising
contacting the cell with an identifier for the presence or expression of an integrin, neurotensin receptor and or ATP-ase; - and
detecting the presence of the identifier. - View Dependent Claims (47)
- and
-
48. Isolated and purified polypeptide from Vero Cells, having approximately a 105 KDa molecular weight and comprising portions with a sequence substantially homologous to SEQ ID NO:
- 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4 and SEQ ID NO;
5.
- 1, SEQ ID NO;
-
49. A polypeptide having a sequence substantially homologous to SEQ ID NO:
- 20 or SEQ ID NO;
21.
- 20 or SEQ ID NO;
-
50. An antibody against a polypeptide from Vero Cells, having approximately a 105 KDa weight and comprising portions with a sequence substantially homologous to SEQ ID NO:
- 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4 and SEQ ID NO;
5.
- 1, SEQ ID NO;
-
51. An antibody against a polypeptide having a sequence substantially homologous to SEQ ID NO:
- 19 or SEQ ID NO;
21.
- 19 or SEQ ID NO;
Specification